Programmed Cell Death-1/Programmed Death-Ligand 1 Blockade Improves Survival of Animals with Sepsis: A Systematic Review and Meta-Analysis

被引:5
|
作者
Zhang, Qiang [1 ]
Qi, Zhijiang [1 ]
Bo-Liu [1 ]
Li, Chun-Sheng [1 ]
机构
[1] Capital Med Univ, Beijing Chao Yang Hosp, Beijing Key Lab Cardiopulm Cerebral Resuscitat, Beijing 100020, Peoples R China
关键词
INDUCED IMMUNOSUPPRESSION; ANTI-PD-L1; ANTIBODY; ADVANCED CANCER; EXPRESSION; PD-1; MORTALITY; IMMUNOTHERAPY; INCREASES; INFECTION; DISEASES;
D O I
10.1155/2018/1969474
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Object. To investigate effects of programmed cell death-1 (PD-1) related blockade in sepsis animals. Methods. Two reviewers independently searched electronic databases including PubMed, EMBASE, and the Cochrane Library up to February 2017. Strict literature retrieval and data extraction were performed to extract relevant data. Data analysis was conducted using RevMan 5.3 software and Stata version 12.0. And relative risks (RRs) for survival rate were calculated. A fixed-effect model was selected to pool and a forest plot was used to display RRs. Results. Four studies involving 394 animals were finally included. Nine control groups are used to pool. A fixed-effect model was applied to estimate a pooled RR of 2.19 (95% CI: 1.74-2.76), indicating that PD-1 related blockade increased survival rate in sepsis animals. Conclusion. We concluded that PD-1 related blockade can improve survival of animals with sepsis. But robust standardized clinical experiments for sepsis patients are highly desirable.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer A Systematic Review and Meta-analysis
    Duan, Jianchun
    Cui, Longgang
    Zhao, Xiaochen
    Bai, Hua
    Cai, Shangli
    Wang, Guoqiang
    Zhao, Zhengyi
    Zhao, Jing
    Chen, Shiqing
    Song, Jia
    Qi, Chuang
    Wang, Qing
    Huang, Mengli
    Zhang, Yuzi
    Huang, Depei
    Bai, Yuezong
    Sun, Feng
    Lee, J. Jack
    Wang, Zhijie
    Wang, Jie
    [J]. JAMA ONCOLOGY, 2020, 6 (03) : 375 - 384
  • [32] Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer
    Arbour, Kathryn C.
    Mezquita, Laura
    Long, Niamh
    Rizvi, Hira
    Auclin, Edouard
    Ni, Andy
    Martinez-Bernal, Gala
    Ferrara, Roberto
    Lai, W. Victoria
    Hendriks, Lizza E. L.
    Sabari, Joshua K.
    Caramella, Caroline
    Plodkowski, Andrew J.
    Halpenny, Darragh
    Chaft, Jamie E.
    Planchard, David
    Riely, Gregory J.
    Besse, Benjamin
    Hellmann, Matthew D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (28) : 2872 - +
  • [33] Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis
    Mori, Keiichiro
    Pradere, Benjamin
    Quhal, Fahad
    Katayama, Satoshi
    Mostafaei, Hadi
    Laukhtina, Ekaterina
    Schuettfort, Victor M.
    D'Andrea, David
    Egawa, Shin
    Bensalah, Karim
    Schmidinger, Manuela
    Powles, Thomas
    Shariat, Shahrokh F.
    [J]. CANCER TREATMENT REVIEWS, 2021, 99
  • [34] Different Programmed Death-1/Programmed Death-Ligand 1 Expression Patterns for Each Pediatric Lymphoma Subtype
    Tamura, A.
    Yoshida, M.
    Yamamoto, N.
    Nino, N.
    Nakatani, N.
    Ichikawa, T.
    Nakamura, S.
    Saito, A.
    Kozaki, A.
    Kishimoto, K.
    Ishida, T.
    Mori, T.
    Hasegawa, D.
    Kosaka, Y.
    [J]. PEDIATRIC BLOOD & CANCER, 2019, 66 : S271 - S271
  • [35] Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy
    Hamid, Omid
    Carvajal, Richard D.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (06) : 847 - 861
  • [36] Cbl-b Deficiency Mediates Resistance to Programmed Death-Ligand 1/Programmed Death-1 Regulation
    Fujiwara, Mai
    Anstadt, Emily J.
    Clark, Robert B.
    [J]. FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [37] Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma
    Mikami, Shuji
    Mizuno, Ryuichi
    Kondo, Tsunenori
    Shinohara, Nobuo
    Nonomura, Norio
    Ozono, Seiichiro
    Eto, Masatoshi
    Tatsugami, Katsunori
    Takayama, Tatsuya
    Matsuyama, Hideyasu
    Kishida, Takeshi
    Oya, Mototsugu
    [J]. CANCER SCIENCE, 2019, 110 (06) : 1820 - 1828
  • [38] Rare Adverse Events with Programmed Death-1 and Programmed Death-Ligand 1 Inhibitors: Justification and Rationale for a Systematic Review (vol 23, 86, 2021)
    Smith, Caleb J.
    Almodallal, Yahya
    Jatoi, Aminah
    [J]. CURRENT ONCOLOGY REPORTS, 2021, 23 (08)
  • [39] Precise medicine of programmed cell death-1/programmed cell death 1 ligand 1 inhibitor immunotherapy combined radiotherapy for inoperable advanced lung cancer A protocol for systematic review and meta-analysis
    Liu, Gang
    Lv, Xiaolan
    Ding, Yanling
    Guo, Yongbo
    [J]. MEDICINE, 2021, 100 (24) : E26367
  • [40] Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature
    Grecea, Miruna
    Marabelle, Aurelien
    Ammari, Samy
    Massard, Christophe
    Champiat, Stephane
    [J]. ONCOLOGIST, 2020, 25 (05): : 369 - 374